Showing results (1-10 of 633) with videos related to
Sort By:
Pageof 64
Diabetes & Metabolism|November 18, 2017
Renal outcomes with dipeptidyl peptidase-4 inhibitorsA J Scheen, P DelanayeDiabetes & Metabolism|February 4, 2017
Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOMEA J Scheen, P DelanayeRevue Medicale De Liege|January 14, 2022
[SGLT2 inhibitors and RAAS blockers : similarities, differences and complementarity]A J Scheen, P DelanayeRevue Medicale De Liege|January 12, 2023
[EMPA-KIDNEY: empagliflozin in chronic kidney disease]P Delanaye, A J ScheenRevue Medicale De Liege|March 8, 2021
[SGLT2 inhibitors in patients with chronic kidney disease : from clinical trials to guidelines and new prospects for clinical practice]A J Scheen, P DelanayeRevue Medicale De Liege|March 8, 2022
[From the discovery of phlorizin (a Belgian story) to SGLT2 inhibitors]H Valdes-Socin, A J Scheen, F Jouret, et al.Clinical Nephrology|May 29, 2009
Estimation of GFR by different creatinine- and cystatin-C-based equations in anorexia nervosaP Delanaye, E Cavalier, R P Radermecker, et al.Revue Medicale De Liege|May 10, 2000
[Clinical study of the month. The STOP-2 study of arterial hypertension in the elderly]A J ScheenRevue Medicale De Liege|September 18, 2002
[Clinical study of the month. The LIPS study: fluvastatin for prevention of cardiac events following percutaneous coronary angioplasty]A J ScheenPageof 64